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Introduction
Purinergic receptor-7 (P2X7R), primarily expressed on lympho-
cytes, senses adenosine 5′-triphosphate (ATP) (1) released extra-
cellularly during cell damage (2, 3) and has been shown to regu-
late T cell activation (4–6). In particular, P2X7R signaling favors 
T helper 1 (Th1) and Th17 generation and differentiation (7–9), 
which are involved in alloimmune responses and allograft rejec-
tion (10–14). Our group has indeed demonstrated a major role for 
the extracellular ATP/P2X7R axis in regulating Th1/Th17 differ-
entiation during cardiac allograft rejection (15–17). Interestingly, 
the opposite T cell immune-polarizing role has been recently 
described for NOD-like receptor P3 (NLRP3) (18), with NLRP3 
acting as a DNA-binding transcriptional factor to promote an 
IL-4–mediated Th2 program in CD4+ T cells (19). The interaction 
between NLRP3 and P2X7R has been described in various cells, 
but not in T lymphocytes (20, 21). We hypothesize that a P2X7R/
NLRP3 pathway within T cells controls Th cell fate, which may be 
dysregulated by mutation of P2X7R, thus driving excessive Th17 
generation, particularly upon allostimulation due to abrogation of 
the NLRP3-mediated Th2 program. Interestingly, a single-nucle-
otide polymorphism (SNP), rs3751143 (p.Glu496Ala/c.1513A>C), 
located in exon 13 of P2X7R, targets the intracellular C-terminal 
portion of P2X7R. This mutation is relatively frequent — with 25% 
of the general population heterozygous and 2% homozygous — 
and results in loss of function of P2X7R (22–29). In this study, we 
have explored the existence of a P2X7R/NLRP3 pathway within 
T cells that controls Th cell fate and the effect of a P2X7R loss-of-
function mutation on this pathway, on Th cell fate, and on clinical 
outcomes in a large cohort of cardiac-transplanted patients.
Results
A P2X7R/NLRP3 pathway exists in CD4+ T cells. Given that an 
interaction between P2X7R and NLRP3 has been documented in 
other cell types (i.e., microglial cells, leukemic cells) (20, 21), we 
initially explored whether a similar association exists in T cells, 
particularly in human CD4+ T cells. We observed that NLRP3 and 
P2X7R reciprocally immunoprecipitated in CD4+ T cells isolated 
from peripheral blood mononuclear cells (PBMCs) obtained from 
human subjects (Figure 1A and Supplemental Figure 1A; supple-
mental material and complete unedited blots available online with 
this article; https://doi.org/10.1172/JCI94524DS1). We then con-
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sion of NLRP3/Th2-related factors was upregulated when CD4+ 
T cells were challenged in vitro with BzATP and downregulated 
when P2X7R inhibitor (CE-224,535) was added (Figure 1, J–M), 
thus supporting the existence of a P2X7R/NLRP3 pathway that 
controls human CD4+ T cell fate. We finally demonstrated the 
absence of a reciprocal link between P2X7R and NLRP3 within 
human CD4+ T cells by showing that NLRP3 blockade using 
siRNA silencing or NLRP3 inhibitor (CP-456773) did not alter 
P2X7R expression (Supplemental Figure 1, B–D).
The P2X7R rs3751143 loss-of-function mutation affects intracel-
lular P2X7R function. The availability of a large cohort of cardiac-
transplanted patient samples and data sets provided by 3 inter-
firmed their colocalization via analysis of immunofluorescence 
distribution at the single-cell level (Figure 1, B and C).
From a functional point of view, we demonstrated an increase 
in NLRP3 expression upon in vitro P2X7R stimulation with ATP 
(BzATP) in CD4+ T cells (Figure 1, D–F) and in CD4+P2X7R+ cells 
(Figure 1, G and H). Conversely, P2X7R blockade with a specific 
inhibitor (CE-224,535) prevented the upregulation of NLRP3 
expression in CD4+ T cells stimulated with benzoyl ATP (BzATP) 
(Figure 1, D–F). Moreover, we confirmed that in CD4+ T cells, the 
activation of P2X7R signaling with BzATP is associated with an 
increase in P2X7R and NLRP3 colocalization (Figure 1I). Further 
analysis of NLRP3 downstream signaling revealed that the expres-
Figure 1. Existence of a P2X7R/NLRP3 pathway within human CD4+ T cells. (A) P2X7R and NLRP3 immunoprecipitation (IP) in human CD4+ T cells. 
Expression of NLRP3 (top blot) and P2X7R (bottom blot) is shown. Lane 1: Total protein. Lane 2: IP with NLRP3 Ab. Lane 3: IP with P2X7R Ab. Lane 4: IP 
with Ab alone (NLRP3 and P2X7R). Lane 5: IP with control IgG (for NLRP3 Ab in top blot, for P2X7R Ab in bottom blot). The experiment was run in triplicate 
(representative blot shown). (B and C) Confocal microscopy analysis (B, scale bar: 5 μm, ×100 original magnification; C, scale bars: 20 μm, ×40 original 
magnification) depicting baseline colocalization of P2X7R (green) and NLRP3 (red) in human CD4+ T cells. Cells were stained with DAPI (blue) and immu-
nolabeled with anti-P2X7R (green) and anti-NLRP3 Abs (red) (n = 3). (D–F) Bar graphs depicting expression of NLRP3 mRNA by qRT-PCR (D), and protein 
by flow cytometry (E) and ELISA (F), evaluated in human CD4+ T cells activated with benzoyl ATP (BzATP) and treated with CE-224,535, a P2X7R inhibitor. 
Experiments were run in duplicate (n = 5). (G) Bar graph representing expression of NLRP3 on human CD4+P2X7R+ cells analyzed by flow cytometry upon 
BzATP stimulation (n = 5). (H) Representative flow dot plots of NLRP3 expression upon gating on human BzATP-stimulated CD4+P2X7R+ cells. (I) Confocal 
analysis (scale bar: 5 μm; ×100 original magnification) depicting colocalization of P2X7R (green) and NLRP3 (red) in CD4+ T cells upon in vitro stimulation 
of P2X7R with BzATP (n = 3). (J–M) Bar graphs comparing expression of NLRP3 downstream signaling Th2-related factors IL-4 (J), IRF4 (K), GATA-3 (L), and 
IL-10 (M) by qRT-PCR using mRNA isolated from human CD4+ T cells activated with BzATP and treated with the P2X7R inhibitor CE-224,535. Experiments 
were run in triplicate (n = 5). Data are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; 1-way ANOVA with Bonferroni’s post 
hoc test or Student’s t test. mRNA expression was normalized to β-actin (ACTB). 
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the effect of the P2X7R mutation, we first conducted transcrip-
tome profiling of immune-relevant genes in CD4+ T cells (Supple-
mental Table 3). Interestingly, this profiling revealed a reduction 
in NLRP3 and P2X7R mRNA expression in CD4+ T cells obtained 
from patients carrying the mutant P2X7R allele as compared 
with noncarrier patients (Figure 2D), suggesting that the interac-
tion between P2X7R and NLRP3 is altered in the presence of the 
P2X7R mutation. Quantitative reverse transcriptase PCR (qRT-
PCR), flow cytometric, and protein expression analysis con-
firmed the downregulation of NLRP3 mRNA (Figure 2E) and pro-
tein (Figure 2, F and G) in CD4+ T cells, particularly in naive but 
not in effector or memory T cell subsets (Supplemental Figure 
2F), and in CD4+P2X7R+ cells, obtained from patients carrying 
the mutant allele (Figure 2, H and I). The near absence of NLRP3 
and its reduced colocalization with P2X7R in CD4+ carrier T cells 
were also confirmed with immunofluorescence studies (Figure 
2, J and K, and Supplemental Figure 2G). Confocal imaging and 
subcellular fractionation studies demonstrated that while NLRP3 
is present in the cytoplasm in CD4+ T cells of noncarrier patients, 
it appears confined to the cell membrane of CD4+ T cells in 
patients carrying the mutant allele (Figure 2, K and L), suggesting 
that the P2X7R mutation may prevent NLRP3 translocation to the 
nucleus. Indeed, chromatin immunoprecipitation (ChIP) experi-
ments revealed that DNA encoding IL-4 and IRF4, the transcrip-
tion factor that in conjunction with NLRP3 transactivates the IL-4 
promoter, was clearly bound to NLRP3 precipitated from CD4+ T 
cells of noncarrier patients, while it was slightly detectably bound 
to NLRP3 precipitated from CD4+ T cells of carrier patients (Fig-
ure 2, M and N), confirming NLRP3 displacement and absence of 
its binding to DNA in the promoter regions of Th2-related genes 
in mutant CD4+ T cells. However, NLRP3 translocation could not 
entirely explain the reduced expression of NLRP3 observed in 
CD4+ T cells of carrier patients. We thus studied the ubiquitin-
mediated degradation of NLRP3 and demonstrated that it was 
accelerated in CD4+ carrier T cells as compared with noncarrier 
cells, and that the addition of the proteasome and ubiquitina-
tion inhibitor MG132 to cultured CD4+ T cells appears to restore 
NLRP3 expression (Figure 2O). NLRP3 is thus not only displaced 
but also is prone to degradation in mutant CD4+ T cells. This may 
also apply to NLRP3 mRNA, which is decreased in CD4+ T cells 
of carriers, as a result of reduced mRNA half-life and acceler-
ated mRNA degradation (Supplemental Figure 2H). We further 
observed reduced levels of the phosphorylated intracellular fac-
tor STAT5, a transcriptional regulator of NLRP3, in CD4+ T cells 
of carriers as compared with noncarriers (Supplemental Figure 
2I), which most likely plays a role in reducing NLRP3 mRNA 
transcription. Finally, we confirmed that epigenetic regulation 
of NLRP3 DNA via NLRP3 promoter methylation was not altered 
in carriers as compared with noncarriers (Supplemental Figure 
2J), and that P2X7R did not directly bind to DNA of NLRP3 or 
NLRP3-related genes (i.e., STAT5, NF-κB, MyD88, IL-10) in 
carrier/noncarrier CD4+ T cells (data not shown) to modulate 
NLRP3 mRNA transcription.
The dysregulated P2X7R/NLRP3 pathway is associated with 
altered Th cell fate. We next confirmed a role for P2X7R/NLRP3 
dysregulation in driving Th cell fate during immune activation. 
In an ex vivo T cell polarization assay in which CD4+ T cells were 
national independent studies (the CTOT-05, the NIT-Bergamo, 
and the AIRT-Bologna) and the recently established crucial role 
of P2X7R signaling in alloimmune response activation led us to 
explore the hypothesis that a mutation in P2X7R may alter T cell 
phenotype/function and ultimately affect cardiac transplantation 
outcomes, by disrupting the regulatory effect of P2X7R on NLRP3 
expression and function.
Intriguingly, the already described P2X7R loss-of-function 
mutation rs3751143 is quite frequent in its homozygous mutated 
state (nearly 2% in the general population, and 7% in cardiac-
transplanted patients), and it mainly targets the C-terminal intra-
cellular domain (24, 25). We thus performed bioinformatic protein 
sequence analysis of P2X7R and determined that the intracellular 
region is predicted to be composed of significant secondary struc-
ture elements, and that mutation of Glu496 likely disrupts some of 
the molecular functions of P2X7R (Figure 2A). We then identified 
carriers of the mutation by genotyping the 413 cardiac-transplant-
ed patients enrolled in the 3 aforementioned studies (Supplemen-
tal Table 1). First, we observed that P2X7R and NLRP3 reciprocally 
immunoprecipitate in CD4+ T cells of carriers, in both the hetero-
zygous and the homozygous state (Supplemental Figure 1A). Next, 
we demonstrated that total protein expression of P2X7R was high-
er in carrier as compared with noncarrier CD4+ T cells (Figure 2B), 
but that surface expression was similar (Supplemental Figure 1, E 
and F). We further observed that P2X7R surface expression did not 
differ in noncarrier CD4+ T cells among different subsets — naive 
(CD4+CD45RO–CCR7+), effector (CD4+CD45RO–CCR7–), and 
memory (CD4+CD45RO+CCR7–) — while it was higher in naive 
CD4+ T cells of carriers as compared with effector and memory 
subsets and compared with naive CD4+ T cells of noncarriers (Sup-
plemental Figure 1G).
To further explore any functional alterations in P2X7R, CD4+ 
T cells were isolated from collected blood samples (Supplemental 
Table 2), and a significant reduction in the BzATP-stimulated intra-
cellular calcium peak (Supplemental Figure 1H) was observed in 
carriers of the mutation as compared with noncarriers, while influx 
of larger cations such as ethidium+ and YO-PRO-1++ was only slight-
ly affected (Supplemental Figure 1, I and J). To further characterize 
the effects of the P2X7R mutation on other cell functions, we ana-
lyzed the intracellular bacterial killing capability of macrophages 
at different time points (24 and 48 hours) and demonstrated that 
this function was not altered in carriers as compared with noncarri-
ers (Supplemental Figure 1K). A reduction in mRNA expression of 
P2X7R was also observed in CD4+ T cells of carriers as compared 
with noncarriers (Figure 2C), but this was paralleled by a rela-
tive increase in mRNA expression of other P2X receptors, such as 
P2X1R and P2X4R (Supplemental Figure 2, A and B). In line with 
this observation, delayed ubiquitination/degradation of the P2X7R 
protein was evident in CD4+ carrier T cells as compared with non-
carriers and resulted in protein accumulation within the cells (Sup-
plemental Figure 2C). This likely leads to reduced P2X7R mRNA 
levels in CD4+ T cells of carriers. Other potential mechanisms such 
as methylation of the P2X7R promoter or altered P2X7R mRNA 
half-life were shown not to be associated with a decrease in P2X7R 
mRNA levels (Supplemental Figure 2, D and E).
Dysregulation of the P2X7R/NLRP3 pathway in CD4+ T cells of 
patients with the P2X7R mutation. In order to better understand 
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nificantly reduced in carrier patients as compared with noncar-
riers (Table 1). This skewing was paralleled by an increase in the 
percentage of Th1/Th17 cells in the circulation (Figure 3, B and C, 
and Table 1) as well as a decrease in Th2 cells in carrier patients 
(Table 1). We further proved the shifted balance toward Th17 by 
differentiated by anti-CD3-Ig/anti-CD28-Ig stimulation in the 
appropriate cytokine milieu for Th1, Th2, or Th17 cells, a skewing 
to the Th17 — and to a lesser extent Th1 — lineage was evident in 
patients carrying the mutant allele as compared with noncarriers 
(Figure 3A and Table 1), and the generation of Th2 cells was sig-
Figure 2. A C-terminal P2X7R mutation dysregulates NLRP3 expression and function in human CD4+ T cells. (A) A 3D representation of the full-length 
structure of P2X7R, highlighting the putative location of the P2X7R mutation in the C-terminal intracellular portion. (B and C) Quantification of P2X7R 
total protein (B, ELISA, n = 3) and of P2X7R mRNA (C, qRT-PCR, n = 10) on CD4+ T cells of carrier and noncarrier patients. Samples were run in duplicate 
(B) or in triplicate (C) and normalized to expression level of β-actin (ACTB). (D) Transcriptome profiling of immune-relevant genes (see also Supplemen-
tal Table 3) examined in CD4+ T cells of carrier and noncarrier cardiac-transplanted patients (n = 5). (E–G) Expression of NLRP3 mRNA using qRT-PCR (E) 
and NLRP3 protein using flow cytometry (F) and ELISA (G) in CD4+ T cells of carrier and noncarrier patients (n = 5). (H and I) Flow cytometric expression 
of NLRP3 on CD4+P2X7R+ cells of carrier patients stimulated with BzATP (n = 5). (J) Percentage of P2X7R+NLRP3+ cells of carrier and noncarrier patients 
analyzed by immunofluorescence (Figure 1C and Supplemental Figure 2G) (n = 3). (K) Confocal microscopy analysis (×100 original magnification) of P2X7R 
(green) and NLRP3 (red) coexpression in CD4+ T cells of carrier patients (n = 3). Scale bar: 5 μm. (L) Subcellular localization of NLRP3 in CD4+ T cells of car-
rier and of noncarrier patients (n = 3). (M and N) IL-4 (M) and IRF4 (N) gene expression detected after ChIP with NLRP3 antibody in CD4+ T cells. (n = 3).  
(O) Quantification of NLRP3 protein measured in CD4+ T cells treated with the ubiquitin/protease inhibitor MG132 (n = 3). Bars represent mean ± SEM.  
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; Student’s t test or 2-way ANOVA with Bonferroni’s post hoc test.
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Th17 cytokines IL-17, IL-6, and IL-22 in the culture supernatants of 
these cells (Figure 3F). Finally, Th17-polarized cells of carriers also 
showed higher production of the proinflammatory cytokines IFN-γ 
and TNF-α, and reduced release of the antiinflammatory cytokine 
IL-1ra (Figure 3F and Supplemental Figure 2L), while no differ-
ence was found with regard to IL-10 (Figure 3F). Moreover, given 
the association of Th17 skewing in immune events occurring after 
transplantation, including cardiac allograft vasculopathy, with the 
development of an autoimmune response against vimentin (30, 
detecting increased peripheral IL-17 levels in the plasma and in the 
supernatants of unstimulated CD4+ T cells of carrier as compared 
with noncarrier patients matched for clinical characteristics (Fig-
ure 3, D and E). In order to better characterize the Th17 shift in car-
rier cells, we demonstrated higher expression of the Th17-related 
markers CCR6, CCR10, and IL-22 — the latter to a lesser degree 
— in differentiated Th17 cells of carriers as compared with non-
carriers by flow cytometric analysis (Figure 3F and Supplemental 
Figure 2K), which was confirmed by increased production of the 
Figure 3. The dysregulated P2X7R/NLRP3 pathway is associated with an abnormal human Th cell immunophenotype. (A) Percentage of in vitro–gen-
erated Th17 cells obtained from CD4+ T cells of carrier and noncarrier patients (n = 8). (B and C) Representative flow zebra plots (B) and quantitative 
histogram (C) depicting the percentage of peripheral CD4+IL-17+ cells (n = 8). (D) IL-17 plasma levels of carrier and noncarrier patients (n = 10). (E) IL-17 levels 
(Luminex) measured in the supernatants of unstimulated 24-hour-cultured CD4+ T cells of carrier and noncarrier patients (n = 5). (F) Table summarizing 
the secretome profile (Luminex, n = 5) and primary phenotypic characteristics (flow cytometry, n = 4) of carrier and noncarrier polarized Th17 cells. (G and 
H) Normalized mRNA expression of Th2-related factors IL-4 (G) and GATA-3 (H) measured in noncarrier CD4+ T cells exposed to transient knockdown of 
NLRP3 using silencing RNA (siRNA), before and after anti-CD3-Ig/anti-CD28-Ig stimulation (n = 3). (I–K) Normalized mRNA expression of the Th2-related 
factors IL-4 (I), IL-10 (J), and GATA-3 (K) measured in noncarrier CD4+ T cells exposed to transient knockdown of NLRP3 (siRNA), upon BzATP exposure (n = 
4). (L and M) Normalized mRNA expression of the Th2-related factors IL-4 (L) and GATA-3 (M) measured in carrier CD4+ T cells, in which NLRP3 was over-
expressed, before and after anti-CD3-Ig/anti-CD28-Ig stimulation (n = 3). (N) Effects of various treatments (anti–IL-17 antibody, RMT1-10, cyclosporin A 
[CsA] and rapamycin [Rapa]) on in vitro–generated Th17 cells (n = 5). Experiments were run in triplicate (D, G, H, and N) or in duplicate (F and I–M). mRNA 
expression was normalized to ACTB. Bars represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; Student’s t test or 1-way ANOVA 
with Bonferroni’s post hoc test.
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31), we demonstrated that, while anti-vimentin autoimmunity 
was detectable, no differences were observed in the anti-vimentin 
immune response in vitro or in peripheral anti-vimentin autoanti-
bodies in carriers as compared with noncarriers (Supplemental Fig-
ure 2, M and N). Fewer peripheral central memory CD4+ and CD8+ 
T cells (CD45RO+CCR7+) paired with a relative increase in effec-
tor memory CD4+ and CD8+ T cells (CD45RO+CCR7–) were evi-
dent as well in carrier as compared with noncarrier patients (Table 
1), thus suggesting an increased effector-type immune response. 
The P2X7R intracellular domain mutation may thus directly 
alter T cell phenotype. Transient genetic overexpression and 
downregulation of NLRP3 were then used to ultimately confirm 
the reciprocal link between the dysregulated P2X7R/NLRP3 path-
way and altered Th cell fate. Silencing of NLRP3 in CD4+ T cells 
of noncarrier patients reduced mRNA expression of Th2-related 
factors (Figure 3, G and H, and Supplemental Figure 3A) and 
was associated with a concomitant increase in the Th17-related 
factor RORc upon stimulation (Supplemental Figure 3B). Unlike 
the silencing of NLRP3 (Figure 3, I–K), inhibition of the inflamma-
some complex by the inhibitor CP-456773 upon ATP triggering 
in CD4+ T cells of noncarrier patients did not alter either the Th2 
profile by flow cytometric analysis (Supplemental Figure 3, C and 
D) or mRNA expression of Th2-related factors (Supplemental 
Figure 3, E–G). Expression of the inflammasome-related factors 
CASP1 and ASC were also unchanged upon NLRP3 silencing but 
were reduced in inflammasome inhibitor–treated cells (Supple-
mental Figure 3, H–K). Overall, this suggests that ATP-triggered 
NLRP3 signaling regulating the Th2 program is inflammasome-
independent. In addition, NLRP3 overexpression in CD4+ T cells 
of carrier patients exerted an opposite effect and restored the Th2 
profile (Figure 3, L and M, and Supplemental Figure 3, L and M).
To finally further establish whether our findings regarding 
P2X7R/NLRP3 dysregulation in T cells are limited to transplant 
patients or are also relevant to the general population, we per-
formed the aforementioned experiments in nontransplanted 
patients (Supplemental Table 4). Indeed, reduced expression 
of NLRP3 in CD4+ T cells (Supplemental Figure 4A), P2X7R/
NLRP3 displacement (Supplemental Figure 4B), reduction in 
Th2 cells, and Th17 skewing in the periphery (Supplemental 
Figure 4, C and D) and during Th2/Th17 generation in vitro 
(Supplemental Figure 4, E and F) were all observed in non-
transplanted carriers compared with noncarriers as well.
Anti–IL-17 neutralizing antibody abrogates the deleterious 
effects of P2X7R loss of function. With the goal of developing 
a personalized therapy for carriers of the mutation, we tested 
whether treatment with an anti–IL-17 neutralizing antibody 
would be effective in abrogating the altered CD4+ T cell phe-
notype in carriers of the P2X7R mutation. Reduced Th17 
skewing was observed when anti–IL-17 neutralizing antibody, 
but not immunosuppressive drugs currently used in trans-
plantation (i.e., rapamycin and cyclosporine) or a Th1 inhibi-
tor, was added to an in vitro Th17 generation assay in which 
CD4+ T cells obtained from carriers were used (Figure 3N). We 
then tested the effect of an anti–IL-17 neutralizing antibody in 
a preclinical model of cardiac transplantation. Surprisingly, 
P2X7R–/– C57BL/6 recipients of bm12 hearts (an established 
MHC class II–mismatched model of chronic allograft vascu-
lopathy) experienced increased allograft loss as compared with 
wild-type C57BL/6 recipients (Figure 4A), with higher levels of 
cell infiltrate, vasculopathy, and myocyte necrosis (Figure 4, B–E). 
Interestingly, treatment with anti–IL-17 neutralizing antibody sig-
nificantly reduced graft loss in P2X7R–/– recipients (Figure 4A) and 
reduced Th17 skewing and immune activation (Figure 4, F–N), as 
assessed by functional studies (Figure 4, F and G), flow cytomet-
ric immunophenotyping (Figure 4, H–M), and cytokine profiling 
(Figure 4, H–J and N). We further confirmed the relevance of the 
P2X7R/NLRP3 pathway in the P2X7R–/– mouse model by demon-
strating that NLRP3 expression is lower within CD4+ T cells than 
in C57BL/6 mice (Figure 4O), and we observed a decreased Th2 
response, particularly with respect to IL-4, upon in vitro and in 
vivo allostimulation (Figure 4, G, J, P, and Q). We acknowledge 
that the murine model is different from cardiac-transplanted 
patients, who are heavily immunosuppressed and receive a fully 
MHC-mismatched cardiac allograft. However, these murine data 
largely parallel our observations in carrier patients (Supplemental 
Table 5), thus suggesting that an anti–IL-17–based treatment may 
help to prevent or delay the onset of immune events in cardiac-
transplanted patients carrying the P2X7R mutation.
The dysregulated P2X7R/NLRP3 pathway is associated with poor 
outcomes in cardiac-transplanted patients. To finally assess the clini-
cal impact of the dysregulated P2X7R/NLRP3 pathway in cardiac-
transplanted patients bearing the P2X7R mutant allele, we studied 
clinical and immunological outcomes of 413 cardiac-transplanted 
patients enrolled in the CTOT-05, NIT-Bergamo, and AIRT-Bolo-
gna international studies. We first confirmed that the frequency 
of the P2X7R mutation in the heterozygous condition was similar 
in the 3 cohorts and in the National Heart, Lung, and Blood Insti-
tute (NHLBI) Grand Opportunity (GO) Exome Sequencing Project 
(ESP) cohort, while the percentage of patients in the homozygous 
mutant condition was lower in the ESP cohort as compared with 
Table 1. Immune phenotype and clinical outcomes in P2X7R mutation 
carrier and noncarrier cardiac-transplanted patients
Noncarrier Carrier P value
Immune phenotype
CD4 effector memory (%) 75.8 ± 1.4 85.9 ± 1.0 0.004
CD8 effector memory (%) 85.7 ± 2.4 74.0 ± 2.5 0.03
CD4 central memory (%) 11.3 ± 1.1 4.1 ± 0.8 0.011
CD8 central memory (%) 12.3 ± 1.4 4.2 ± 0.6 0.003
Regulatory T cells (%) 2.7 ± 0.2 2.9 ± 0.4 NS
CD4+IL-17+ (%) 5.5 ± 0.8 11.7 ± 0.8 0.001
CD4+IFN-γ+ (%) 9.8 ± 0.5 18.0 ± 1.8 0.0007
CD4+IL-10+ (%) 20.8 ± 3.8 8.4 ± 2.1 0.03
CD4+IL-4+ (%) 15.6 ± 0.4 7.7 ± 1.1 0.0001
Th1 cell generation (%) 5.0 ± 1.0 11.0 ± 0.4 0.002
Th2 cell generation (%) 9.8 ± 0.5 6.5 ± 0.3 0.001
Immune events
MIT > 0.5 mm at 1 year, number (%) 9/62 (14.5) 13/40 (32.5) 0.04
ARs (n > 3) at 1 year, number (%) 92/111 (83) 66/70 (94) 0.03
MACEs at 10 years, number (%) 27/91 (29.7) 22/39 (56.4) 0.005
AR, acute rejection; MACE, major adverse cardiac event; MIT, maximal intimal 
thickness.
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what was observed in cardiac-transplanted patients (nearly 7.5%) 
(Supplemental Table 6).
We next analyzed an early outcome in the CTOT-05 cohort 
by examining what proportion showed an incremental change 
greater than 5 mm in intracoronary ultrasonography–measured 
coronary artery maximal intimal thickness (MIT), which defines 
rapidly progressive cardiac allograft vasculopathy following heart 
transplantation. A significant increase in MIT was observed in 13 
of 40 carriers (32.5%), and in 9 of 62 noncarrier patients (14.5%; 
P = 0.04; Figure 5A). Carrying the mutant allele was thus associat-
ed with an increased odds ratio (OR) for developing an incremen-
tal change in coronary artery MIT within the first year after trans-
plant (OR = 2.83, CI 1.1–7.4, P = 0.04; Table 1), and this association 
was confirmed after controlling for the most relevant modifying 
factors (age, sex, pretransplant cardiomyopathy, and immunosup-
pressive therapy) as shown in Supplemental Table 7. We then stud-
ied in the NIT-Bergamo cohort the number of clinically assessed 
and/or biopsy-proven acute rejection episodes, observing an 
increased frequency of events in carrier as compared with noncar-
rier patients (10.4 ± 0.5 vs. 8.7 ± 0.4, P = 0.01; Figure 5B) within 
the first year after transplantation, with a higher proportion of 
patients experiencing more than 3 acute rejection events per year 
(66/70 [94%] in carriers vs. 92/111 [83%] in noncarrier patients, 
P = 0.03; Table 1). Carrying the mutant allele was thus associated 
with an increased OR for developing a higher number of acute 
rejection episodes within the first year after transplant (OR = 3.40, 
CI 1.1–10.5, P = 0.04; Table 1), which was confirmed after control-
ling for other factors potentially involved (age, sex, pretransplant 
Figure 4. P2X7R loss of function in a preclinical model of heart transplantation reduces allograft survival, with increased vasculopathy and Th1/Th17–
mediated responses. (A) P2X7R–/– mice receiving bm12 heart transplantation demonstrated reduced graft survival as compared with B6 recipients (**P < 
0.01), which was significantly prolonged by anti–IL-17 treatment (murine IL-17–depleting antibody) (*P < 0.05 vs. P2X7R–/–) (n = 10 mice per group). (B–D) 
Semiquantification of graft infiltration (B), coronary vasculopathy (C), and myocyte necrosis (D) confirmed accelerated allograft rejection in P2X7R–/– mice 
(n = 3). (E) Representative H&E staining (x20 original magnification) showing graft cell infiltration (top panels), vasculopathy (middle panels), and myo-
cyte necrosis (bottom panels) in B6 and P2X7R–/– mice. Scale bars: 200 μm (middle panels), 300 μm (top and bottom panels). (F and G) Numbers of IFN-γ–
producing (F) and IL-4–producing (G) cells (ELISPOT) measured in cardiac-transplanted mice (n = 3). (H–M) Percentage of CD4+IL-17+ (H), CD4+IFN-γ+ (I), 
CD4+IL-10+ (J), CD4+CD44hiCD62Llo (K), CD8+CD44hiCD62Llo (L), and CD4+CD25+Foxp3+ (M) cells detected by flow cytometry in B6 and P2X7R–/– cardiac-trans-
planted mice and in P2X7R–/– anti–IL-17–treated mice (n = 5). (N) Serum IL-17 level (Luminex) measured in B6 and P2X7R–/– cardiac-transplanted mice and 
in P2X7R–/– anti–IL-17–treated mice (n = 5). (O) Percentage of CD4+NLRP3+ cells analyzed by flow cytometry in P2X7R–/– and B6 mice (n = 3). (P) Number of 
IL-4–producing cells (ELISPOT) in P2X7R–/– and B6 mice upon allostimulation (n = 3). (Q) Serum IL-4 level (Luminex), measured in B6 and P2X7R–/– cardiac- 
transplanted mice (n = 5). Samples were run in duplicate (Luminex) and in triplicate (ELISPOT). Bars represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 
0.001; ****P < 0.001; log-rank (Mantel-Cox) test (A), Wilcoxon’s and Student’s t test (2 groups), 1-way ANOVA with Bonferroni’s post hoc test (3 groups). 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3 4 9 7jci.org   Volume 128   Number 8   August 2018
Figure 5. A C-terminal P2X7R mutation is associated with poor outcomes in cardiac-transplanted patients. (A) Bar graph depicting the percentage of 
cardiac-transplanted patients who carry the WT or mutant P2X7R allele (n = 102) with an MIT change greater than 0.5 mm (early cardiac allograft vasculop-
athy, in black) at 1 year after transplantation in the CTOT-05 cohort. (B) Bar graph depicting the number of acute rejection episodes in cardiac-transplanted 
patients who carry the WT (black) or mutant (white) P2X7R allele (n = 181) within the first year after transplant in the NIT-Bergamo cohort. (C) Bar graph 
depicting the percentage of cardiac-transplanted patients who carry the WT or mutant P2X7R allele (n = 130) with major adverse cardiac events (MACEs, 
in black) at 10 years of follow-up in the AIRT-Bologna cohort. In A and C: black, percentage of patients who experienced the event; white, percentage 
who were free from events. (D) Line graph depicting the estimated odds ratio (OR) for clinical outcomes recorded in the 3 cohorts of cardiac-transplanted 
patients who carry the WT or mutant P2X7R allele. In the NIT-Bergamo cohort, the OR was calculated based on the requirement of medical intervention 
for acute rejection episodes with a frequency of greater or less than 3 episodes. *P < 0.05; **P < 0.01. Supplemental Tables 7–9 report detailed analyses. 
Fisher’s exact and Student’s t tests. (E and F) A stable connection between P2X7R and NLRP3 is necessary to establish a physiological NLRP3-mediated 
Th2 program (E), while alteration in the P2X7R intracellular domain induces NLRP3 displacement and retains NLRP3 in the cell membrane, thus preventing 
its nuclear activity and accelerating ubiquitination of NLRP3 (F). This shifts the balance of the immune response toward Th17 cells and favors the develop-
ment of immune-related events, such as allograft rejection and vasculopathy. Ub, ubiquitin; eATP, extracellular ATP.
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abrogates the abnormal Th17 skewing in human T cells in vitro 
and prolongs cardiac allograft survival in preclinical models. 
This immunophenotype has a clear impact on clinical outcomes 
as demonstrated by our 3 independent international studies (the 
CTOT-05, the NIT-Bergamo, and the AIRT-Bologna cohorts), 
which demonstrated an increased frequency of clinical events 
(i.e., rapidly progressive cardiac allograft vasculopathy, number 
of acute rejection episodes, and number of MACEs, respectively), 
even when adjusted for other variables involved.
Our results were also confirmed in a group of nontransplanted 
patients, among whom reduced expression of NLRP3 in CD4+ T 
cells, displacement of P2X7R/NLRP3, reduction in Th2 cells, and 
Th17 skewing (both in the periphery and during Th2/Th17 genera-
tion in vitro) were observed in carriers as compared with noncarri-
ers. Further studies are certainly needed to confirm this observa-
tion in a larger population, but these data suggest that carriers of 
the mutant P2X7R allele may represent a population of patients 
with a fragile immune system at risk of developing a hyper-Th17 
syndrome in response to various immune stimulations (e.g., infec-
tions, inflammation, or tissue damage).
Some limitations of our study should be noted. Firstly, the 
bm12 into C57BL/6 heart transplantation murine model does 
not faithfully replicate the condition of cardiac transplantation 
in humans, given minor HLA mismatching, a reduced degree of 
transplant atherosclerosis, and the lack of a concomitant immu-
nosuppression therapy in this model. Secondly, with respect to 
human studies, a larger cohort would have certainly provided 
greater statistical power to the association between P2X7R muta-
tion and immune disorders. Thirdly and finally, the complexity 
of the clinical assessment in our study, which included multiple 
outcomes evaluated at different time points, as well as the het-
erogeneity in clinical practice among study centers, may reduce 
the strength of this analysis. Future studies would benefit from 
improvement upon these limitations, with the rate of immune 
events in patients with the P2X7R mutation as a primary endpoint.
In summary, the P2X7R/NLRP3 complex maintains a physio-
logical NLRP3-mediated Th2 program, while intracellular muta-
tion of P2X7R induces NLRP3 displacement in T cells, causing 
Th17 skewing and resulting in poor allograft outcome (Figure 5, 
E and F). Our study demonstrates, for the first time to our knowl-
edge, the existence of a novel mechanism controlling T cell fate 
and delineates a group of cardiac-transplanted patients with 
Th17 skewing and with worse clinical and immunological out-
comes, as well as identifies a population who may benefit from 
selective targeted therapy.
Methods
A detailed description of the methods used in this study is provided in 
the Supplemental Methods.
Genotyping of P2X7R rs3751143
DNA was extracted from anticoagulated peripheral blood sam-
ples obtained from each patient using the Qiagen QIAamp DNA 
Blood Mini Kit (51104, Qiagen). Genotypes were determined using 
an Applied Biosystems TaqMan Human SNP Genotyping Assay 
(4351376, Thermo Fisher Scientific) for rs3751143 in accordance with 
the manufacturer’s protocol.
cardiomyopathy, and immunosuppressive therapy; Supplemental 
Table 8). Finally, we analyzed the long-term impact of the muta-
tion and observed in the AIRT-Bologna cohort an increased fre-
quency of major adverse cardiac events (MACEs) within 10 years 
after transplantation in 22 of 39 carriers (56.4%) compared with 
27 of 91 noncarrier patients (29.7%; P = 0.005; Figure 5C). Carry-
ing the mutant allele was thus associated with an increased OR for 
developing MACEs after transplantation also in the long term (OR 
= 3.07, CI 1.4–6.6, P = 0.006; Table 1), which was confirmed after 
adjustment for clinically relevant factors (age, sex, pretransplant 
cardiomyopathy, and immunosuppressive therapy), as reported 
in Supplemental Table 9. Despite the heterogeneity in practice 
among study centers (e.g., suboptimal standardization of clinical-
ly relevant outcomes, decision algorithm for immunosuppressive 
and/or other treatments), our findings collectively demonstrate 
that the dysregulated P2X7R/NLRP3 pathway in cardiac-trans-
planted patients bearing the P2X7R mutant allele is associated 
with an increased risk of developing poor outcomes such as rap-
idly progressive cardiac allograft vasculopathy and higher fre-
quency of acute rejection episodes and long-term MACEs follow-
ing transplantation (Figure 5D).
Discussion
This study offers a novel understanding of the mechanisms that 
may control Th cell fate by suggesting that P2X7R exerts a regu-
latory effect on NLRP3 within CD4+ T cells, which is required to 
maintain NLRP3 in the proper intracytoplasmic/nuclear position 
and in an operative mode, thus facilitating its nuclear action (i.e., 
interaction with the IL-4 promoter and IRF4) and Th2 commit-
ment. Moreover, in our study a group of patients at high risk for 
immune events related to dysregulation of the P2X7R/NLRP3 
pathway and who may require personalized therapy has been 
identified. We demonstrated that mutation of the P2X7R intra-
cellular region affects Th cell fate, favoring skewing toward Th17 
generation, leading to a more pronounced effector/inflammatory 
phenotype and thus exposing patients to the risk of allograft loss. 
Given the importance of the Th17 response in allograft rejection 
(32), understanding the mechanism whereby the mutation of 
P2X7R favors Th17 skewing is highly clinically relevant. Interest-
ingly, we observed that this mutation in the P2X7R intracellular 
region directly favors NLRP3 displacement and redirects NLRP3 
to the cell membrane compartment. This prevents the nuclear 
transcriptional and DNA binding activity of NLRP3, as well as 
results in its accelerated ubiquitination and rapid proteolysis, 
thus abrogating NLRP3-mediated Th2 differentiation (19) and 
inducing Th17 skewing. While ubiquitination is a key mecha-
nism in regulating NLRP3 activation within cells that helps to 
maintain its transcriptional activity (33, 34), we discovered that 
proper function of the P2X7R/NLRP3 pathway appears to be 
crucial in rescuing NLRP3 from ubiquitin-mediated degrada-
tion and in preserving its function within T cells. A genetic add-
back experiment confirmed the link between the dysregulated 
P2X7R/NLRP3 pathway and altered Th skewing. Transient trans-
genic overexpression of NLRP3 rescues the Th2 program in CD4+ 
T cells carrying the mutant allele, while siRNA downregulation 
of NLRP3 abrogates it, thus promoting Th17 skewing in CD4+ 
T cells obtained from noncarriers. Interestingly, IL-17 blockade 
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enyi Biotec) according to the manufacturer’s instructions. The purity 
of the isolated CD4+ T cell population routinely exceeded 95%. 
Flow cytometry and intracellular cytokine staining of human cells. 
Primary antibodies included anti–human CD45 (560178), CD4 
(561030), CD8 (560774), CD25 (560503), CCR7 (557648), CD127 
(557938), IFN-γ (554702), IL-4 (554484), IL-10 (554498) (all BD Bio-
sciences); IL-17 (12-7178-41), CD45RO (MHD45R005) (both Thermo 
Fisher Scientific); and CD3 (300330, BioLegend). FITC-conjugated 
anti–mouse P2X7R (APR-008-F) was purchased from Alomone Labs. 
Alexa Fluor 700–conjugated anti–human NLRP3 (IC7578N) was pur-
chased from R&D Systems. Purified anti–human NLRP3 (IC7578G) 
and Alexa Fluor 488–conjugated anti–rabbit NLRP3 (IC7578G) were 
purchased from R&D Systems and BD Biosciences, respectively. Rest-
ing cells were activated with PMA (5 ng/ml; 13-144, Sigma-Aldrich) 
and ionomycin (500 ng/ml; 13909, Sigma-Aldrich) for 3 hours; then 
brefeldin A (2 μM; B7651, Sigma-Aldrich) was added. Cells were 
harvested in FACS tubes and placed on ice. Cells were then washed 
with FACSFlow (342003, BD Biosciences) and processed for intra-
cellular cytokine staining with saponin 0.5% (47036, Sigma-Aldrich) 
and formaldehyde 2% (F8775) for fixation and permeabilization. 
Anti–phospho-STAT5–PE (pY694, clone 47, 562077, BD Biosciences) 
was used to assess intracellular phospho-STAT5 expression per the 
manufacturer’s instructions.
Human Th cell differentiation. CD4+ T cells isolated from recovered 
PBMCs were stimulated with anti-CD3-Ig (1 μg/ml; HMCD0300, Life 
Technologies), anti-CD28-Ig (2 μg/ml; CD2800, Life Technologies), 
and rIL-2 (50 U/ml; 202-IL, R&D Systems). For Th1 differentiation, 
rIL-12 (2.5 ng/ml; 219-IL, R&D Systems) and anti–IL-4 (5 μg/ml; 204-
IL, R&D Systems) were added. For Th2 differentiation, rIL-4 (12.5 ng/
ml; 504-RL, R&D Systems), anti–IFN-γ (5 μg/ml; AHC4032, Invitro-
gen), and anti–IL-10 (5 μg/ml; 501505, BioLegend) were added. For 
Th17 differentiation, rIL-1β (1290-IL, R&D Systems), rIL-6 (206-IL, 
R&D Systems), and rTGF-β (240-B, R&D Systems) (final concentra-
tion 10 ng/ml) were added. After 4 days, cells were harvested and 
stained for FACS analysis. Th1 cells were defined as producing IFN-γ, 
Th2 cells were defined as producing either IL-4 or IL-10, and Th17 
cells were defined as producing IL-17. For detailed Th17 character-
ization, the expression of CCR6 (563922, BD Biosciences), CCR10 
(56769, BD Biosciences), and IL-22 (12-7229-41, Thermo Fisher Sci-
entific) was also assessed.
Human peripheral IL-17 levels. Levels of IL-17 were measured using 
an IL-17 Human Quantikine ELISA kit (D1700, R&D Systems) per the 
manufacturer’s instructions. Plasma samples from cardiac-transplant-
ed patients (Supplemental Table 2) and from nontransplanted patients 
were diluted per kit protocol and analyzed by an ELISA plate reader 
according to the manufacturer’s instructions.
Luminex cytokine measurement. Levels of cytokines were assessed 
in culture supernatants of CD4+ T cells using the Bio-Plex Pro human 
cytokine 17-plex panel (M5000031YV, Bio-Rad) according to the 
manufacturer’s protocol. The Hu Th17 IL-22 set (171BA008M, Bio-
Rad) was used to detect IL-22.
Intracellular calcium response of human CD4+ T cells. Isolated 
PBMCs were thawed, and recovered CD4+ T cells were purified as 
described above. CD4+ T cells were then cultured in RPMI 1640 (Life 
Technologies) supplemented with 10% FBS, 2 mM l-glutamine, and 
100 U/ml penicillin (Life Technologies). After 48 hours, cells were 
resuspended at 1 × 107 cells/ml and incubated in 2.5 μM fluo-3AM 
Study cohorts and clinical endpoints
In order to study the effects of rs3751143, we have established a large 
international cohort of 747 cardiac-transplanted patients, which 
includes the US-based Clinical Trials in Organ Transplantation-05 
(CTOT-05) cohort, the Northern Italian Transplant (NIT, Bergamo, 
Italy) group, and the Inter-Regional Transplant Association (AIRT, 
Bologna, Italy). Genotype and immunological and clinical outcomes 
were evaluated in all patients (Supplemental Table 1).
The CTOT-05, an observational study designed to understand the 
natural history of cardiac allograft vasculopathy, comprises 200 cardiac- 
transplanted patients enrolled in the United States from June 2007 
to July 2011. Coronary artery vasculopathy, as defined by a change in 
MIT of ≥0.5 mm through intracoronary ultrasonography (IVUS) (35) 
between study entry and 12 months, was assessed. Of the 200 patients 
enrolled in the CTOT-05, 148 were genotyped, and IVUS was per-
formed in 102 patients.
The NIT cohort consists of 187 patients who underwent cardiac 
transplantation at Divisione Cardiovascolare, Ospedali Riuniti in Ber-
gamo, Italy, from 1985 to 2012. Acute rejection episodes, either clini-
cally assessed and/or proven by biopsy, were recorded over a period of 
12 months after transplant. Patients were grouped according to num-
ber of episodes (either higher or lower than 3) that required medical 
intervention and/or hospitalization within the first year. Of the 187 
patients enrolled, 187 were genotyped, and acute rejection episodes 
were observed in 181 patients.
The AIRT cohort consists of 360 cardiac-transplanted patients 
followed within the Heart Failure and Heart Transplant Program at 
the Department of Experimental Diagnostic and Specialty Medicine, 
S. Orsola Hospital in Bologna, Italy, between 1985 and 2013. Clini-
cal outcome was defined by the occurrence of major adverse cardiac 
events (MACEs), which included nonfatal myocardial infarction, 
coronary revascularization, and hospitalization for graft failure, over 
a long-term follow-up (10 years) from the time of transplantation (36). 
Of the 360 patients enrolled, 359 were genotyped, and data on MACEs 
for follow-up of at least 10 years from the time of transplantation were 
available in 130 patients.
Patients carrying the mutant allele for P2X7R in either the homozy-
gous or the heterozygous state were included in the analysis of clinical 
outcome. Blood was collected according to the following timeline: 1.1 ± 
0.4 years of follow-up in the CTOT-05 cohort; 5 ± 1.2 years of follow-up 
in the NIT-Bergamo cohort; and 15 ± 0.8 years of follow-up in the AIRT-
Bologna cohort. Fifty healthy volunteers matched for age and sex were 
chosen as controls (Supplemental Table 4). The study was approved by 
the ethics committee of each participating institution.
Immunological studies
PBMC isolation and CD4+ T cell purification. PBMCs were isolated from 
10-ml blood samples collected from cardiac-transplanted patients 
(Supplemental Table 2) and from nontransplanted patients using Lym-
phoprep (07801, Stem Cell Technologies) according to the manufac-
turer’s instructions. Cells were then frozen in vials containing 5 × 106 
cells/ml and stored at –80°C. After thawing, PBMCs were recovered in 
culturing medium consisting of RPMI 1640 (31870017, Life Technolo-
gies) supplemented with 10% FBS (12103C-500ML, Sigma-Aldrich), 
2 mM l-glutamine (25030081, Life Technologies), 100 U/ml penicil-
lin (15140122, Life Technologies), for 48 hours, and CD4+ T cells were 
then isolated using a CD4 Positive Isolation Kit (130-090-877, Milt-
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isolation of cells. The main characteristics of primers used are report-
ed in Supplemental Table 10.
Immunoprecipitation
Isolated CD4+ T cells obtained from carrier and noncarrier patients 
were incubated on ice for 45 minutes in lysis buffer containing 150 
mM NaCl, 5 mM EDTA, 20 mM Tris, pH 7.5, 1% Triton X-100, 1 mM 
benzamidine, 1 mM phenylmethylsulfonyl ﬂuoride, and protease 
inhibitor cocktail (P8340, Sigma-Aldrich). Lysates were centrifuged at 
20,000 g for 5 minutes before precipitation. Total protein content of 
cell lysates was measured with the Bradford assay. Dynabeads Protein 
A (10001D, Life Technologies) were used for immunoprecipitation 
according to the manufacturer’s instructions. Dynabeads were pre-
incubated with polyclonal rabbit anti-NLRP3 (768319, R&D Systems) 
and polyclonal rabbit anti-P2X7R (P8232-2ML, Sigma-Aldrich) anti-
bodies before addition of lysates (20).
Immunoblotting. Total proteins of CD4+ T cell samples were 
extracted in Laemmli buffer (Tris-HCl 62.5 mmol/l, pH 6.8, 20% 
glycerol, 2% SDS, 5% β-mercaptoethanol), and their concentration 
was measured. Thirty-five micrograms of total protein was elec-
trophoresed on 7% SDS-PAGE gels and blotted onto nitrocellulose 
(10401196, Schleicher & Schuell). Blots were then stained with Pon-
ceau S. Membranes were blocked for 1 hour in TBS (Tris 10 mmol/l, 
NaCl 150 mmol/l), 0.1% Tween-20, 5% nonfat dry milk, pH 7.4 at 
25°C, incubated for 12 hours with rat anti-NLRP3 (MAB7578, R&D 
Systems) diluted 1:250 or with rabbit anti-P2X7R (P8232, Sigma-
Aldrich) diluted 1:200 in TBS–5% milk at 4°C, washed 4 times with 
TBS–0.1% Tween-20, then incubated with goat anti-rat–HRP (sc-
2006, Santa Cruz Biotechnology) or goat anti-rabbit–HRP (P0448, 
Agilent Technologies) diluted 1:500 in TBS–5% milk, and finally 
washed with TBS–0.1% Tween-20. The resulting bands were visu-
alized using enhanced chemiluminescence (32132, SuperSignal, 
Pierce Biotechnology Inc.).
Immunofluorescence
Immunofluorescence analysis of CD4+ T cells was performed using 
the following primary antibodies: rat anti-NLRP3 (MAB7578, R&D 
Systems) with a 1:100 dilution and rabbit anti-P2X7 (P8232, Sigma-
Aldrich) at a 1:50 dilution. Secondary antibodies were as follows: 
donkey anti-rat–TRITC (712-025-150, Jackson ImmunoResearch) and 
donkey anti-rabbit–FITC (711-095-152, Jackson ImmunoResearch), 
at a 1:50 dilution. Analysis of immunofluorescence and collection of 
images were conducted using a confocal system (TCS SP5 laser scan-
ning confocal, Leica).
Quantification of NLRP3 and P2X7R protein
CD4+ T cells extracted from PBMCs of carrier and noncarrier 
patients were lysed according to the manufacturer’s instructions. 
Briefly, cells were pelleted and supernatants removed by centrifu-
gation. Cells were then resuspended in PBS after 3 washing steps 
and lysed by ultrasonication 4 times. Cellular debris was further 
removed by centrifugation, and supernatant was collected for use in 
ELISA (NLRP3 and P2X7R: MBS917009 and MBS9426859, respec-
tively, from LSBio) according to the manufacturer’s instructions. 
Levels of NLRP3 or P2X7R protein, normalized per milligram or 
microgram of total protein and/or per cell number when applicable, 
were assessed and calculated.
(73881, Sigma-Aldrich) for 45 or 60 minutes at 25°C and then dilut-
ed and used at 2 × 106 or 4 × 106 cells per time point. Calcium peak 
response and area under the curve were measured upon stimulation 
with 500 μM benzoyl ATP (BzATP; B6396, Sigma-Aldrich).
Large cation dye uptake of human CD4+ T cells. Isolated CD4+ T 
cells obtained from PBMCs of carrier and noncarrier patients were 
resuspended in NaCl medium (145 mM NaCl, 5 mM KCl, 5 mM glu-
cose, 0.1% BSA, 10 mM HEPES, pH 7.5), equilibrated at 37°C for 5 min-
utes, and incubated with 25 μM ethidium+ or 1 μM YO-PRO-1++ in the 
absence or presence of BzATP (2 mM) for 5 minutes. Incubation with 
nucleotides was halted by the addition of an equal volume of ice-cold 
NaCl medium (20 mM MgCl2) followed by centrifugation (300 g for 
5 minutes). Cells were washed once with NaCl medium, and events 
were collected using a BD FACS Celesta (BD Biosciences) (excitation 
488 nm, emission collected with 575/26 PE and 515/20 FITC band-
pass filters for ethidium+ and YO-PRO-1++, respectively) (37). Mem-
brane integrity was assessed using the BD Horizon Fixable Viabil-
ity Stain 510 kit (564406, BD Biosciences) to exclude dead cells. The 
mean fluorescence intensity of relative cation uptake was determined 
using FlowJo software (version 8, Tree Star).
Interventional in vitro studies
Anti–IL-17 (10 μg/ml; MAB3171-100, R&D Systems), CE-224,535 (50 
μM; provided by Pfizer), RMT1-10 (100 μg/ml; BE0133, BioXCell), 
rapamycin (6 ng/ml; R8781, Sigma-Aldrich), and cyclosporine (100 
ng/ml; PHR1092, Sigma-Aldrich) were used in vitro in a Th17 assay 
using concentrations already tested and described or according to 
blood levels used in drug monitoring (17, 38–42). Cells were stimu-
lated with BzATP (50 μM) for 24 hours to activate P2X7R in vitro as 
previously described (20). The effect of inflammasome activation was 
tested by addition of the inflammasome inhibitor CP-456773 (200 
μM; PZ0280, Sigma-Aldrich) to short-term BzATP (5 mM) stimulation 
for 1 hour in vitro as already described (43).
Transcriptome profiling
Total RNA was extracted from CD4+ T cells isolated from PBMCs 
obtained from each group of patients, using the RNeasy Mini Kit 
(74104, Qiagen) with on-column DNase I digestion. Next, 3 μg total 
RNA from each sample was reverse-transcribed using the RT2 First 
Strand kit (330401, SABiosciences). The Human Inflammasome 
RT2 Profiler PCR Array (PAHS-097Z, Qiagen) platform was used to 
quantitatively measure the expression of a panel of genes using SYBR 
Green–based real-time PCR (Supplemental Table 3).
qRT-PCR analysis
RNA from isolated CD4+ T cells was extracted using TRIzol Reagent 
(15596026, Ambion), and quantitative reverse transcriptase PCR 
(qRT-PCR) analysis was performed using TaqMan assays (Life Tech-
nologies) according to the manufacturer’s instructions. qRT-PCR 
data were determined using the relative quantification method, and 
ACTB served as a reference housekeeping gene. Statistical analysis 
compared gene expression across all cell populations for each patient 
via 1-way ANOVA followed by Bonferroni’s post hoc test for multiple 
comparisons between the population of interest and all other popula-
tions. Statistical analysis was performed also using the software RT2 
profiler PCR Array Data Analysis (Qiagen). For 2-group comparisons, 
Student’s t test was used. Analysis was performed in triplicate after 
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minutes and at baseline and 30 and 90 minutes, respectively, in order 
to evaluate ubiquitin-mediated degradation. The ubiquitin inhibitor 
MG132 (M8699, Sigma-Aldrich) was added in order to block ubiqui-
tin-mediated degradation, and NLRP3 or P2X7R was quantified at the 
same time points described above (44, 45).
Bioinformatic analysis and protein modeling
The P2X7R intracellular sequence (from residues 360–595) was sub-
mitted to I-TASSER algorithms for 3D protein structure prediction as 
previously described (46), producing 10 models, the best of which had 
a normalized Z score of 1.17.
Bacterial killing
CD14+ cells were isolated from PBMCs of carrier and noncarrier 
patients using CD14 microbeads (130-050-201, Miltenyi), followed 
by cell culture over 7 days in RPMI 1640 supplemented with 10% FBS, 
25 mM HEPES, M-CSF (50 ng/ml), penicillin (100 U/ml), and strepto-
mycin (100 mg/ml). Cells were then coincubated with equal numbers 
of E. coli for 24 and 48 hours. Lysates obtained were plated onto agar 
plates, and viable bacteria were counted (CFU) (47, 48).
ELISPOT autoimmune assay
An ELISPOT assay (552138, BD Biosciences) was used to measure 
IFN-γ production by responder cells when restimulated with vimen-
tin peptide (2105-VI, R&D Systems) (31). Vimentin peptide (20 μg/
ml), anti-CD3- and anti-CD28-Ig (1 μg/ml and 2 μg/ml, respectively; 
CD0300 and CD2800, Life Technologies), tetanus toxoid mixture 
(1 μl; Diftavax, Sanofi Pasteur), or IA-2 (100 μg/ml; Pierce Biotech-
nology Inc.) was used to stimulate 1 × 105 responder PBMCs obtained 
from carrier and noncarrier patients for 48 hours. Spots were count-
ed using an ImmunoSpot analyzer (CTL Europe GmbH) as previ-
ously described (15).
Statistics
Continuous variables are presented as means and standard errors, 
and categorical variables are presented as proportions. We used inde-
pendent sample t tests to compare continuous variables and χ2 test/
Fisher’s exact test to compare categorical variables. For multiple com-
parisons, 1-way or 2-way ANOVA followed by Bonferroni’s post hoc 
test between the group of interest and all other groups was used. All 
multivariable analyses were adjusted for age and sex. Univariable and 
multivariable logistic regression methods were used to model the rela-
tionships between risk factors and outcomes of interest. Two-tailed 
P values less than 0.05 were considered statistically significant.
Study approval
Human and animal studies were approved by the appropriate insti-
tutional review board(s) of Boston Children’s Hospital (Boston, Mas-
sachusetts, USA); Ospedale S. Orsola Malpighi (Bologna, Italy); and 
Ospedali Riuniti di Bergamo (Bergamo, Italy). Written informed con-
sent was received from participants prior to inclusion in the study. 
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NLRP3 small RNA interference and overexpression
CD4+ T cells obtained from noncarrier transplanted patients were cul-
tured in vitro with or without anti-CD3/anti-CD28 stimulation. After 
24 hours of culture, 750 ng of small interfering RNA (siRNA; Flexi-
tube siRNA SI02634030, Qiagen) in 100 μl culture medium without 
serum and with 6 μl HiPerFect Transfection Reagent (301704, Qia-
gen) was incubated to allow for formation of transfection complexes. 
Analysis of NLRP3 gene silencing was performed at 24 and 48 hours 
by evaluation of the mRNA expression of Th2- and Th17-related fac-
tors. Control siRNA was used as a negative control to confirm the 
effect of gene silencing. CD4+ T cells obtained from transplanted 
carrier patients were cultured in vitro with or without anti-CD3/
anti-CD28 stimulation. NLRP3-overexpressing CD4+ T cells were 
obtained by transfection with Lipofectamine 2000 (11668-019, Life 
Technologies) per the manufacturer’s instructions. The NLRP3 plas-
mid (RG220952) was provided by OriGene.
Subcellular localization
Subcellular fractionation of CD4+ T cells was performed using the 
Qiagen Qproteome Cell Compartment kit (37502, Qiagen), which 
enables the sequential isolation of proteins associated with the cyto-
sol, membranes, nucleus, and cytoskeleton from cell lysates.
Briefly, cells were isolated as previously described and then pel-
leted. Cytosolic extraction buffer was added, and the respective frac-
tion was isolated by centrifugation. Addition of membrane extraction 
buffer was used to obtain the membrane fraction per the manufac-
turer’s instructions. Expression of NLRP3 and of P2X7R was further 
assessed in each fraction using an ELISA kit as described above. 
NLRP3 or P2X7R in each cell fraction was reported as picograms per 
microgram of total NLRP3 or P2X7R, and data were expressed as per-
centage of NLRP3 or of P2X7R detected in each compartment.
Assessment of NLRP3 DNA binding using modified ChIP
We performed chromatin immunoprecipitation (ChIP) using an Aga-
rose ChIP Kit (26156, Thermo Fisher Scientific). Briefly, CD4+ T cells 
were isolated as above, and protein-DNA complexes were stabilized 
and then extracted. In vivo cross-linking was achieved with formal-
dehyde. To lyse, extract, and solubilize the cross-linked complexes, 
the Thermo Fisher Scientific Chromatin Prep Module was used 
(included in the kit), thus reducing contamination of the chromatin-
bound DNA from other cellular compartments and enriching sam-
ples for NLRP3. Once chromatin was digested, immunoprecipitation 
of NLRP3 was performed as described above (see “Immunoprecipi-
tation”). To analyze protein-binding sequences, genomic DNA was 
sheared into small pieces with enzymatic digestion per the manufac-
turer’s instructions. After proteinase digestion and cross-link rever-
sal, DNA was purified, and expression of genes of interest (IRF4, 
IL-4) was assessed using a TaqMan Copy Number Assay 
(Hs0201197cn, Hs00092447cn, Applied Biosystems). Expression of 
genes was normalized to that of total non-immunoprecipitated DNA 
extracted from the same number of cells.
Ubiquitin-mediated culturing experiments
CD4+ T cells isolated from carrier and noncarrier PBMCs were cul-
tured as previously described in the presence of an inhibitor of protein 
synthesis, cycloheximide (C4859-1ML, Sigma-Aldrich), and NLRP3 
and P2X7R protein was quantified at baseline and 30, 60, 90, and 120 
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